Genmab A/S
GNMSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $96,544 | $139,217 | $194,138 | $166,956 |
| - Cash | $9,858 | $14,867 | $9,893 | $8,957 |
| + Debt | $1,029 | $770 | $597 | $425 |
| Enterprise Value | $87,715 | $125,120 | $184,842 | $158,424 |
| Revenue | $21,526 | $16,474 | $14,595 | $8,482 |
| % Growth | 30.7% | 12.9% | 72.1% | – |
| Gross Profit | $20,541 | $16,248 | $14,595 | $8,482 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| EBITDA | $9,697 | $5,991 | $7,328 | $4,179 |
| % Margin | 45% | 36.4% | 50.2% | 49.3% |
| Net Income | $7,844 | $4,352 | $5,452 | $2,957 |
| % Margin | 36.4% | 26.4% | 37.4% | 34.9% |
| EPS Diluted | 121.36 | 66.02 | 82.59 | 45.54 |
| % Growth | 83.8% | -20.1% | 81.4% | – |
| Operating Cash Flow | $7,771 | $7,380 | $3,912 | $2,228 |
| Capital Expenditures | -$187 | -$376 | -$317 | -$252 |
| Free Cash Flow | $7,584 | $7,004 | $3,595 | $1,976 |